FDA rejects Daiichi Sankyo's application for pain medication
The FDA issued a complete response letter in response to Daiichi Sankyo's new drug application regarding CL-108, a drug used in treating and managing pain. Read More »
The FDA issued a complete response letter in response to Daiichi Sankyo's new drug application regarding CL-108, a drug used in treating and managing pain. Read More »
Precision for Value and the National Committee for Quality Assurance have partnered to integrate data collected in the Healthcare Effectiveness Data and Information Set into the quality measuring tool Qnav. Read More »
The Pharmaceutical Research and Manufacturers of America submitted comments this month to the 2017 Special 301 Report. Read More »